Slate Bio Launches with Seed Financing to Develop Next Generation IL-2 Therapies
In All, PortfolioCHARLOTTESVILLE, Va. —Slate Bio, Inc., announced today the closing of a $1.75 million venture financing. Epidarex Capital led the investment round with participation from the UVA Licensing & Ventures Group Seed Fund, Center for Innovative Technology’s GAP BioLife Fund, VTC Seed Fund, PharmaDirections, Inc., management and others….